Stocks in Action USA: Sarepta Therapeutics, Arm Holdings, Chewy
Reading Time: 4 minutes
Sarepta Therapeutics (SRPT) – The gene therapy specialist delivers promising study data and ignites new hope in the field of rare muscle diseases! The stock of Sarepta Therapeutics reacts with a strong price surge after the company released initial clinical data from its siRNA pipeline. The focus is on the drug candidates SRP-1001 and SRP-1003 for the treatment of the rare muscle diseases FSHD1 and DM1. In early Phase 1/2 studies, both programs show a clear dose-dependent uptake in muscle tissue and a measurable effect on key disease markers....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
